Group 1 - The company held its 23rd meeting of the 4th Board of Directors on September 4, 2025, to discuss various proposals, all of which were approved unanimously by the attending directors [2][3]. - The board approved a proposal to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance global development strategy and optimize capital structure [2][5][12]. - The issuance of H-shares will not exceed 15% of the total share capital post-issuance, subject to market conditions and regulatory approvals [12][14]. Group 2 - The board agreed on the issuance method, which includes public offerings in Hong Kong and international placements, with specific allocation strategies based on demand and investor qualifications [9][10][19]. - The board approved the use of proceeds from the H-share issuance for global expansion, technology development, capacity upgrades, and general corporate purposes [27][30]. - The company will transition to a foreign-funded joint-stock company after the H-share issuance and listing, allowing it to be publicly listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange [30][32]. Group 3 - The board proposed to cancel the supervisory board, transferring its responsibilities to the audit committee, and to revise the company's articles of association accordingly [78][79]. - The company will appoint a new independent director and adjust the board's specialized committees to enhance governance structure [42][46]. - The board plans to hold a second extraordinary general meeting in 2025 to review the proposals discussed in the board meeting [73].

证券代码：688639 证券简称：华恒生物 公告编号：2025-034 安徽华恒生物科技股份有限公司 第四届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届董事会第二 十三次会议于 2025 年 9 月 4 日在公司会议室以现场结合通讯方式召开。会议 通知已于 2025 年 8 月 25 日以专人递送方式送达全体董事。本次会议应出席董 事 9 名，实际出席董事 9 名。本次会议由董事长郭恒华女士召集并主持。本次 会议的召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司发行 H 股股票并在香港联合交易所有限公司上 市的议案》 为深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行 业领先地位，充分借助国际资本市场的资源与机制优势，优化资本结构，拓宽 多元融资渠道，全面提升公司治理水平和综合实力，公司拟发行境外上市 ...

Core Viewpoint - Guangdong Chaohongji Industrial Co., Ltd. plans to issue H shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness, as well as to advance its internationalization strategy [1][2]. Group 1: Board Meeting Decisions - The board meeting held on June 9, 2025, approved the proposal to issue H shares with a unanimous vote of 9 in favor [1][2]. - The issuance of H shares will be conducted as public offerings in Hong Kong and international placements, with the total number of H shares not exceeding 15% of the company's total share capital post-issuance [3][4]. - The board has the authority to determine the specific issuance timing based on market conditions and regulatory approvals [2][3]. Group 2: Issuance Details - The H shares will have a par value of RMB 1.00 and will be offered in foreign currency [2][3]. - The pricing of the H shares will consider the interests of existing shareholders and market conditions at the time of issuance [4][5]. - The distribution of shares will be based on the number of valid applications received during the public offering in Hong Kong, with a potential "reallocation" mechanism for oversubscription [5][6]. Group 3: Fund Utilization - The funds raised from the H share issuance will be used for expanding domestic and international business, enhancing brand influence, improving research and production capabilities, and supplementing working capital [9][10]. - If the raised funds are insufficient for project needs, the company will seek alternative funding solutions [10]. Group 4: Regulatory Compliance and Governance - The company will apply to convert into an overseas fundraising company and will comply with relevant laws and regulations [9][10]. - The board will be authorized to handle all matters related to the H share issuance and listing, including communication with regulatory bodies [12][14]. - The company plans to appoint Ernst & Young as the auditing firm for the H share issuance [11][12]. Group 5: Internal Governance Adjustments - The company will revise its internal governance documents to align with the requirements of the H share issuance and listing [21][22]. - The board will establish a "Strategic and ESG Committee" to enhance governance post-listing [21][22]. Group 6: Future Meetings and Elections - The board has proposed to hold the first extraordinary shareholders' meeting of 2025 to discuss the H share issuance and related matters [30]. - The election of Lin Junping as the vice chairman of the board was approved [30].

Core Viewpoint - Shanghai Hehe Information Technology Co., Ltd. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global capital operation capabilities and brand recognition, while also revising its corporate governance structure and internal rules to align with this strategic move [6][9][24]. Group 1: Shareholder Meeting Proposals - Proposal to cancel the supervisory board and amend the company's articles of association, transferring the supervisory board's powers to the audit committee of the board of directors [6][24]. - Proposal for the issuance of H-shares and listing on the Hong Kong Stock Exchange, which has been approved by the board and supervisory board [9][14]. - Proposal to authorize the board of directors to handle all matters related to the H-share issuance and listing [17][23]. Group 2: Governance and Internal Rules - Proposals to revise various internal governance documents, including the rules for shareholder meetings, board meetings, and independent director work systems, to ensure compliance with new regulations following the H-share issuance [7][8][24]. - The company plans to adjust its internal governance documents based on changes in laws and regulations, as well as the requirements of regulatory bodies [20][24]. Group 3: Fund Utilization - The funds raised from the H-share issuance will be used for enhancing AI technology research, product innovation, global expansion, and general corporate purposes [16][24]. - The board seeks authorization to adjust the use of raised funds based on operational needs and regulatory feedback [21][24].